2 recruiting, 1 completed, 1 terminated, 1 withdrawn. 5 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Recruiting 2, Completed 1, Terminated 1, Withdrawn 1 |
| Phase 2 | 1 | Withdrawn 1 |
Follow Solid Tumor Malignancy: new trials by email Literature Review of Solid Tumor Malignancy trials Research Report on Solid Tumor Malignancy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety Trial of 68Ga/177Lu-NRT6020 in FAP-Positive Advanced Solid Tumor Patients 68Ga-NRT6020 Injection, 177Lu-NRT6020 Injection (stage 2), 177Lu-NRT6020 Injection (stage 3) - Solid Tumor Malignancy | Phase 1 | Recruiting | Chengdu New Radiomedicine Technology Co. LTD. | 132 | 2025-11-29 | 2026-02-02 |
| A Clinical Trial of SIBP-A18 Injection in the Treatment of Advanced Malignant Solid Tumor Patients SIBP-A18 - Solid Tumor Malignancy | Phase 1 | Recruiting | Shanghai Institute Of Biological Products | 156 | 2025-06-16 | 2026-01-07 |
| A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors XL495, ADC cytotoxic agents - Solid Cancers, Solid Tumor Cancer | Phase 1 | Terminated | Exelixis | 9 | 2024-10-17 | 2025-06-25 |
| Selinexor Combination Ph 1 Study Selinexor, Irinotecan - Solid Tumor Malignancy | Phase 1 / Phase 2 | Withdrawn | Martin Gutierrez | 2014-09-01 | 2022-01-04 | |
| Safety Study Of SNX-5422 To Treat Solid Tumor Cancers And Lymphomas SNX-5422 Mesylate Hsp90 inhibitor - Solid Tumor Malignancy, Lymphoid Malignancy (Lymphoma and CLL) | Phase 1 | Completed | Esanex Inc. | 32 | 2008-03-01 | 2012-05-17 |
Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Leukemia (1) · Lymphoma (1) · Neoplasm Metastasis (1)
Neoplasms (2) · Neoplasms by Histologic Type (2) · Adenocarcinoma (1) · Carcinoma (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Kidney Diseases (1) · Kidney Neoplasms (1) · Lymphatic Diseases (1) · Lymphoproliferative Disorders (1) · Male Urogenital Diseases (1)
Irinotecan (1) · selinexor (1)
Chengdu New Radiomedicine Technology Co. LTD. (1) · Esanex Inc. (1) · Exelixis (1) · Martin Gutierrez (1) · Shanghai Institute Of Biological Products (1)
United States (3) · China (2)